Cedric Hermans/LinkedIn
Aug 13, 2025, 23:32
Cedric Hermans Shares His Vision for the Use of APCC During Emicizumab Prophylaxis
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, recently shared on LinkedIn:
”Personal commentary on the recent important paper by Robert Sidonio et al. on APCC in patients receiving emicizumab prophylaxis published in RPTH.”
Read the full article here.
Article: Cautious use of activated prothrombin complex concentrate in patients receiving emicizumab: new evidence and clinical considerations
Author: Cedric Hermans
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Apr 12, 2026, 16:53Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
-
Apr 12, 2026, 16:36Piotr Czempik: Patient Blood Management Means Safer Care, Better Quality, and Responsible Resource Use
-
Apr 12, 2026, 16:31Eishi Asano: Available Evidence and Unmet Needs in EEG Use During Stroke Management
-
Apr 12, 2026, 16:23Jack Shuang Hou: CorTec Wins 1st-Ever FDA Breakthrough Device Designation for BCI in Stroke Motor Rehabilitation
-
Apr 12, 2026, 15:54Ralf Illing: Proud to Contribute My Patient Voice to OCEANIC-STROKE Research
-
Apr 12, 2026, 15:38Hugo Antonio Romo Rubio: ASH ISTH 2026 Guidelines on Prophylactic Anticoagulation In Pediatrics
-
Apr 12, 2026, 15:26Melissa Lewellyn: The DVT and PE Awareness Resolution from NBCA Is Now Live
-
Apr 12, 2026, 14:58Akram Shibani: HI-PEITHO Trial Reminds Us Why Composite Endpoints Deserve Careful Scrutiny
-
Apr 12, 2026, 14:493 Days, 14 Leaders, 1 Mission at The 13th EHC Youth Leadership Workshop